GSK has announced Luke Miels will succeed Emma Walmsley as CEO from 1 January 2026. Currently Chief Commercial Officer, he has driven growth in GSK’s specialty medicines, especially oncology and respiratory. With experience at AstraZeneca, Roche, and Sanofi-Aventis, Miels plans to guide GSK towards a $40 billion sales target by 2031.